H2 Equity Partners (“H2”) is pleased to announce that it has signed a definitive agreement for the sale of its minority shareholding in Optegra Eye Health Care, the fast-growing and highly integrated ophthalmology platform operating in five key European markets: the UK, Czech Republic, Poland, Slovakia and the Netherlands, to EssilorLuxottica (“EL”).

Joining forces with EssilorLuxottica marks a transformative chapter for Optegra. EL’s global leadership in vision care, combined with Optegra’s clinical excellence and patient-centric approach, creates an innovative platform to redefine the paradigm of ophthalmic services.

H2 acquired a majority stake in Optegra in February 2021 and has invested significant resources and capital to accelerate its growth. Alongside the Optegra management team, H2 realised substantial growth and development of the business, opening new UK hospitals, completing several bolt-on acquisitions as well as entering a new geographic market, Slovakia. As a result, revenues and profitability experienced strong growth cementing Optegra as one of the leading ophthalmology groups in Europe.

In November 2022 H2 agreed to divest Optegra to MidEuropa Partners, a leading private equity firm with deep roots in Central Europe. As part of that transaction, H2 re-invested part of its proceeds to continue to support the further development of Optegra and retain a minority stake.

The transaction with EssilorLuxottica as announced today will mark the end of H2’s highly successful involvement with Optegra. We are proud of our achievements and wish the entire Optegra team continued success in the future.

The transaction is conditional on certain customary closing conditions and is expected to complete later in 2025.